Overview Dividends

(NAMS) NewAmsterdam Pharma - Ratings and Ratios

Exchange: NASDAQ • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: NL00150012L7

Obicetrapib, Ezetimibe, CETP Inhibitor

Risk via 10d forecast
Volatility 69.2%
Value at Risk 5%th 93.1%
Relative Tail Risk -18.23%
Reward TTM
Sharpe Ratio 0.93
Alpha 42.16
Character TTM
Hurst Exponent 0.465
Beta 0.810
Beta Downside 0.992
Drawdowns 3y
Max DD 66.23%
Mean DD 22.56%
Median DD 21.96%

Description: NAMS NewAmsterdam Pharma November 11, 2025

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is a late-stage biotechnology firm based in Naarden, the Netherlands, focused on developing oral therapies for metabolic disorders.

The lead asset, obicetrapib, is a low-dose CETP inhibitor being evaluated both as monotherapy and in combination with ezetimibe to lower LDL-C in cardiovascular disease patients, and it is also in a Phase 2a trial for Alzheimer’s disease.

As of the most recent quarter, the company reported a cash runway of roughly 18 months and a market capitalization near $120 million, positioning it to fund ongoing Phase 2 studies without immediate dilution. The CETC inhibitor market is projected to grow at a CAGR of ~7 % through 2030, driven by unmet demand for oral lipid-lowering agents that can complement statin therapy.

For a deeper quantitative view of NAMS’s valuation metrics and risk profile, you may find it worthwhile to explore the analyst tools on ValueRay.

NAMS Stock Overview

Market Cap in USD 4,349m
Sub-Industry Biotechnology
IPO / Inception 2022-11-23
Return 12m vs S&P 500 68.5%
Analyst Rating 4.56 of 5

NAMS Dividends

Currently no dividends paid

NAMS Growth Ratios

Metric Value
CAGR 3y 56.51%
CAGR/Max DD Calmar Ratio 0.85
CAGR/Mean DD Pain Ratio 2.51
Current Volume 1306.9k
Average Volume 883.8k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-221.1m TTM) > 0 and > 6% of Revenue (6% = 2.11m TTM)
FCFTA -0.18 (>2.0%) and ΔFCFTA 15.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 1913 % (prev 1181 %; Δ 732.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.18 (>3.0%) and CFO -144.4m > Net Income -221.1m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 12.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (119.0m) change vs 12m ago 25.59% (target <= -2.0% for YES)
Gross Margin 99.55% (prev 99.91%; Δ -0.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 5.75% (prev 7.65%; Δ -1.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -89.96 (EBITDA TTM -288.1m / Interest Expense TTM 3.21m) >= 6 (WARN >= 3)

Altman Z'' -12.42

(A) 0.86 = (Total Current Assets 732.3m - Total Current Liabilities 58.3m) / Total Assets 786.4m
(B) -0.87 = Retained Earnings (Balance) -687.5m / Total Assets 786.4m
(C) -0.47 = EBIT TTM -288.3m / Avg Total Assets 612.8m
(D) -11.46 = Book Value of Equity -668.7m / Total Liabilities 58.4m
Total Rating: -12.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 33.59

1. Piotroski 0.0pt
2. FCF Yield -3.96%
3. FCF Margin data missing
4. Debt/Equity 0.00
5. Debt/Ebitda 1.87
6. ROIC - WACC (= -46.92)%
7. RoE -29.07%
8. Rev. Trend -0.71%
9. EPS Trend 57.25%

What is the price of NAMS shares?

As of November 21, 2025, the stock is trading at USD 37.71 with a total of 1,306,906 shares traded.
Over the past week, the price has changed by +3.54%, over one month by +0.13%, over three months by +55.06% and over the past year by +88.46%.

Is NAMS a buy, sell or hold?

NewAmsterdam Pharma has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy NAMS.
  • Strong Buy: 5
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the NAMS price?

Issuer Target Up/Down from current
Wallstreet Target Price 45.5 20.8%
Analysts Target Price 45.5 20.8%
ValueRay Target Price 54.3 44%

NAMS Fundamental Data Overview November 18, 2025

Market Cap USD = 4.35b (4.35b USD * 1.0 USD.USD)
P/S = 123.3873
P/B = 5.9723
Beta = 0.058
Revenue TTM = 35.2m USD
EBIT TTM = -288.3m USD
EBITDA TTM = -288.1m USD
Long Term Debt = 266.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 181.0k USD (from shortTermDebt, last quarter)
Debt = 266.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -538.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.65b USD (4.35b + Debt 266.0k - CCE 702.9m)
Interest Coverage Ratio = -89.96 (Ebit TTM -288.3m / Interest Expense TTM 3.21m)
FCF Yield = -3.96% (FCF TTM -144.5m / Enterprise Value 3.65b)
FCF Margin = -410.1% (FCF TTM -144.5m / Revenue TTM 35.2m)
Net Margin = -627.3% (Net Income TTM -221.1m / Revenue TTM 35.2m)
Gross Margin = 99.55% ((Revenue TTM 35.2m - Cost of Revenue TTM 160.0k) / Revenue TTM)
Gross Margin QoQ = 81.61% (prev 99.76%)
Tobins Q-Ratio = 4.64 (Enterprise Value 3.65b / Total Assets 786.4m)
Interest Expense / Debt = 1205 % (Interest Expense 3.21m / Debt 266.0k)
Taxrate = -0.0% (0.0 / -72.0m)
NOPAT = -288.3m (EBIT -288.3m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 12.57 (Total Current Assets 732.3m / Total Current Liabilities 58.3m)
Debt / Equity = 0.00 (Debt 266.0k / totalStockholderEquity, last quarter 728.1m)
Debt / EBITDA = 1.87 (negative EBITDA) (Net Debt -538.1m / EBITDA -288.1m)
Debt / FCF = 3.72 (negative FCF - burning cash) (Net Debt -538.1m / FCF TTM -144.5m)
Total Stockholder Equity = 760.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.11% (Net Income -221.1m / Total Assets 786.4m)
RoE = -29.07% (Net Income TTM -221.1m / Total Stockholder Equity 760.4m)
RoCE = -37.90% (EBIT -288.3m / Capital Employed (Equity 760.4m + L.T.Debt 266.0k))
RoIC = -37.92% (negative operating profit) (NOPAT -288.3m / Invested Capital 760.4m)
WACC = 9.00% (E(4.35b)/V(4.35b) * Re(9.0%) + (debt cost/tax rate unavailable))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 20.12%
Fair Price DCF = unknown (Cash Flow -144.5m)
EPS Correlation: 57.25 | EPS CAGR: 220.9% | SUE: -0.50 | # QB: 0
Revenue Correlation: -0.71 | Revenue CAGR: -63.36% | SUE: -0.42 | # QB: 0

Additional Sources for NAMS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle